Abstract: Objective: To compare the clinical effects and safety pemetrexed combined with platinum and other platinum duplex regimens for treating non-drive gene positive advanced lung adenocarcinoma. Methods: 120 cases of non-drive gene positive advanced lung adenocarcinoma patients were divided into experimental group (n=55) and control group (n=65) according to treatment. The patients in experimetal group were treated with pemetrexed combined with platinum regimens, while the patients in control group were treated with TP(taxol+cisplatin) / DP(docetaxel+cisplatin) / GP(gemcitabine+cisplatin) chemotherapy regimens. The curative effects and safety of patients in 2 groups were evaluated after 4 treatment cycles. Results: The overall response rate (ORR), disease control rate (DCR), overall survival (OS), 1 year survival rate of patients in experimental group were obviously higher than control group (P<0.05). The incidence rate of thrombocytopenia, leukopenia and anemia of patients in experimental group were obviously lower than control group (P<0.05). Conclusions: Compared with TP/DP/GP regimen, treating non-drive gene positive advanced lung adenocarcinoma with PC regimen can get more significant effects and less adverse reactions, so it is worthy to be popularized in clinic.

Key words: Advanced lung adenocarcinoma, Non-drive gene positive, Pemetrexed, Cisplatin

摘要： 目的: 比较培美曲塞联合铂类化疗方案与其它铂二联化疗方案治疗非驱动基因阳性晚期肺腺癌的临床疗效及安全性。方法: 120例非驱动基因阳性晚期肺腺癌初治患者根据治疗方案分为实验组55例和对照组65例,实验组选用PC（培美曲塞+顺铂）方案、对照组选用TP（紫杉醇+顺铂）/DP（多西他赛+顺铂）/GP（吉西他滨+顺铂）方案化疗,4个周期后评价疗效及安全性。结果: 实验组总缓解率（ORR）、疾病控制率（DCR）、总生存期（OS）、1年生存率显著高于对照组,血小板减少、白细胞减少及贫血发生率明显低于对照组,差异有统计学意义（P<0.05）。结论: 应用PC方案治疗非驱动基因阳性的晚期肺腺癌较应用TP/DP/GP方案临床疗效更显著,且不良反应轻,值得临床上大力推广。

关键词: 晚期肺腺癌, 非驱动基因阳性, 培美曲塞, 顺铂